Counterfeiting, Compliance, and Controls

Published on: 
Pharmaceutical Technology, Pharmaceutical Technology-09-02-2003, Volume 27, Issue 9

FDA and manufacturers seek to curb drug counterfeiting while legislators consider liberalizing drug importing policies to cut pharmaceutical costs.

Related Content:

Regulatory Oversight and ComplianceSupply ChainManufacturingPharmaceutical Technology-09-02-2003
CARBOGEN AMCIS Shanghai Site Gets Drug Manufacturing License from China’s NMPA
Roche to Invest $50 Billion in US Pharmaceuticals and Diagnostics
Paige, Sonrai Form Partnership to Harness AI for Precision Medicine R&D